TLDR CrowdStrike reports third-quarter earnings Tuesday with analysts expecting 20% revenue growth to $1.2 billion Annual recurring revenue projected to rise 22% to $4.9 billion as company continues recovery from July 2024 outage Stock has surged over 130% since August 2024 low following the software update incident that affected 8.5 million devices Company now trades [...] The post CrowdStrike (CRWD) Stock: Earnings Report Set for Tuesday With 20% Revenue Growth Expected appeared first on CoinCentral.TLDR CrowdStrike reports third-quarter earnings Tuesday with analysts expecting 20% revenue growth to $1.2 billion Annual recurring revenue projected to rise 22% to $4.9 billion as company continues recovery from July 2024 outage Stock has surged over 130% since August 2024 low following the software update incident that affected 8.5 million devices Company now trades [...] The post CrowdStrike (CRWD) Stock: Earnings Report Set for Tuesday With 20% Revenue Growth Expected appeared first on CoinCentral.

CrowdStrike (CRWD) Stock: Earnings Report Set for Tuesday With 20% Revenue Growth Expected

2025/12/02 18:02
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • CrowdStrike reports third-quarter earnings Tuesday with analysts expecting 20% revenue growth to $1.2 billion
  • Annual recurring revenue projected to rise 22% to $4.9 billion as company continues recovery from July 2024 outage
  • Stock has surged over 130% since August 2024 low following the software update incident that affected 8.5 million devices
  • Company now trades at 77 times projected free-cash-flow-per-share, nearly double the 40x multiple of its industry peers
  • Wall Street analysts have maintained their estimates over the past 30 days with adjusted earnings expected at $0.94 per share

CrowdStrike reports third-quarter earnings Tuesday afternoon. The cybersecurity company faces high expectations from Wall Street.

Analysts project revenue of $1.2 billion for the quarter. That represents 20% growth compared to last year.


CRWD Stock Card
CrowdStrike Holdings, Inc., CRWD

Adjusted earnings are expected to hit $0.94 per share. This figure matches roughly what the company reported in the same quarter of fiscal 2025.

The year-over-year comparisons don’t tell the full story this time. CrowdStrike changed how it calculates adjusted earnings per share earlier this fiscal year. The new method significantly lowered the measurement.

The company also shifted its customer payment structure. Clients can now commit to longer-term contracts. This change boosts long-term sales but delays revenue recognition in the near term.

Annual recurring revenue provides a clearer picture for subscription software companies. Analysts expect this metric to climb 22% to $4.9 billion.

Recovery From July Outage Continues

The earnings come as CrowdStrike moves past the July 2024 incident. A faulty software update crashed 8.5 million Windows devices worldwide. Microsoft confirmed the scope of the outage.

The technical nature of the bug meant each PC and server required manual fixes. That created a massive workload for IT teams.

CrowdStrike shares dropped 11% on the day of the outage. The decline continued through August. The stock lost 36% of its value during that period.

The company handled the crisis with aggressive customer support. Management distributed free products and services to retain clients. New procedures were implemented to prevent similar incidents.

Sales growth has been trending down since 2019 when it exceeded 100%. The rate has now stabilized around 20%. That’s still considered strong growth for a company of this size.

Delta Air Lines has filed a lawsuit over damages from the outage. This remains the main legal liability facing the company.

Valuation Concerns Mount

The stock has roared back since hitting bottom in August 2024. Shares have climbed more than 130% from that low point.

This rally pushed the valuation into expensive territory. CrowdStrike trades at 77 times projected free-cash-flow-per-share for the next 12 months.

The S&P 500 Software and Services Industry Group trades at 40 times the same metric. CrowdStrike commands nearly double the multiple of its peers.

The company has beaten revenue estimates consistently. Over the past two years, it missed Wall Street’s projections just once. On average, it exceeded expectations by 1.4%.

Last quarter delivered a 1.7% revenue beat with sales of $1.17 billion. That represented 21.3% year-over-year growth.

Analysts covering the stock have held steady on their estimates over the past 30 days. This suggests they expect business conditions to remain stable heading into the report.

Peers in the cybersecurity space showed mixed results in their recent quarters. Varonis Systems reported 9.1% revenue growth but missed estimates by 2.7%. Qualys beat expectations by 2.2% with 10.4% revenue growth.

CrowdStrike shares are down 8.3% over the past month. The broader cybersecurity group has fallen 5.2% in the same period. Analysts maintain an average price target of $533.26 compared to the current price around $506.51.

The post CrowdStrike (CRWD) Stock: Earnings Report Set for Tuesday With 20% Revenue Growth Expected appeared first on CoinCentral.

Market Opportunity
RISE Logo
RISE Price(RISE)
$0,003318
$0,003318$0,003318
+1,87%
USD
RISE (RISE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

CME Group to launch options on XRP and SOL futures

CME Group to launch options on XRP and SOL futures

The post CME Group to launch options on XRP and SOL futures appeared on BitcoinEthereumNews.com. CME Group will offer options based on the derivative markets on Solana (SOL) and XRP. The new markets will open on October 13, after regulatory approval.  CME Group will expand its crypto products with options on the futures markets of Solana (SOL) and XRP. The futures market will start on October 13, after regulatory review and approval.  The options will allow the trading of MicroSol, XRP, and MicroXRP futures, with expiry dates available every business day, monthly, and quarterly. The new products will be added to the existing BTC and ETH options markets. ‘The launch of these options contracts builds on the significant growth and increasing liquidity we have seen across our suite of Solana and XRP futures,’ said Giovanni Vicioso, CME Group Global Head of Cryptocurrency Products. The options contracts will have two main sizes, tracking the futures contracts. The new market will be suitable for sophisticated institutional traders, as well as active individual traders. The addition of options markets singles out XRP and SOL as liquid enough to offer the potential to bet on a market direction.  The options on futures arrive a few months after the launch of SOL futures. Both SOL and XRP had peak volumes in August, though XRP activity has slowed down in September. XRP and SOL options to tap both institutions and active traders Crypto options are one of the indicators of market attitudes, with XRP and SOL receiving a new way to gauge sentiment. The contracts will be supported by the Cumberland team.  ‘As one of the biggest liquidity providers in the ecosystem, the Cumberland team is excited to support CME Group’s continued expansion of crypto offerings,’ said Roman Makarov, Head of Cumberland Options Trading at DRW. ‘The launch of options on Solana and XRP futures is the latest example of the…
Share
BitcoinEthereumNews2025/09/18 00:56
Why YouCam AI API is the Secret Weapon for E-Commerce Startups

Why YouCam AI API is the Secret Weapon for E-Commerce Startups

 The New Standard of Personalized Shopping In an era where digital engagement dictates market share, the transition from “browsing” to “buying” depends on confidence
Share
Techbullion2026/03/25 14:34
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26